The U.S. Food and Drug Administration (FDA) has long prioritized increasing the representativeness of clinical trial populations, acknowledging that diverse and inclusive participation is essential for the development of therapies that are effective across the heterogeneous American populace. Recent meetings convened by the FDA’s Oncologic Drug Advisory Committee (ODAC) highlighted a growing apprehension: approvals of emerging oncologic therapies are being hampered, at least in part, by questions surrounding the applicability of trial outcomes, especially when patient enrollment fails to reflect the demographic and geographic diversity of the broader population affected by NSCLC. This regulatory scrutiny underscores the urgency of ensuring that clinical research is both representative and generalizable.

In an effort to elucidate these distributional trends, Brittany Avin McKelvey, PhD, a senior director of regulatory policy at the LUNGevity Foundation, spearheaded an analytical review focused on the spatial and temporal dynamics of phase I NSCLC trial sites. By mining data from ClinicalTrials.gov, her team cataloged all interventional, industry-sponsored phase I trials initiated from January 2020 through December 2024. The methodology entailed mapping unique site addresses associated with distinct National Clinical Trial (NCT) numbers, thereby quantifying both the number of active unique sites and the instances of trial initiations. This granular approach enabled a comprehensive portrait of how clinical trial site engagement evolved over the five-year interval.

Across the global landscape, 555 phase I NSCLC trials commenced during this timeframe, accounting for 8,393 trial instances spread over 47 countries. The United States represented the lion’s share, hosting 45% of these trial instances, followed by China (11%), Spain (8%), Korea (5%), France (4%), and Australia (4%). While the aggregate number of trial instances increased in the U.S. from 819 in 2020 to a peak of 955 in 2022, a subsequent decline to 566 by the close of 2024 was observed. Analogous downward trends were mirrored in other significant jurisdictions such as China, Spain, Korea, and France, whereas countries like Australia, Japan, and Brazil displayed modest upward trajectories.

A particularly disconcerting finding was the sharp contraction in the number of unique trial sites within the United States, which contracted from 395 to 223 over the studied interval. However, this reduction in breadth was offset by a stable volume of trials being concentrated within a narrow cadre of top-tier sites. The 20 highest-volume sites maintained a median annual initiation rate of seven to eleven trials each across the five years, predominantly located in cities with populations exceeding 1.9 million residents. This centralization presents a paradoxical divergence from the FDA’s stated objectives advocating decentralization and broader community-based trial access.

The implications of this trend are multifaceted. Centralizing trials at large, established institutions may enhance operational efficiencies, facilitate access to cutting-edge technologies, and leverage extensive clinical expertise. Yet, it simultaneously risks creating barriers to trial participation for patients residing outside major cities, effectively limiting geographical and socioeconomic diversity within the trial cohorts. This uneven access may dampen the generalizability of trial results and inadvertently bias therapeutic development in favor of patient populations concentrated near these eminent centers.

Several underlying factors have been posited to drive this consolidation phenomenon. Phase I trials, by nature, are characterized by complex and rigorous protocols coupled with the administration of novel agents whose safety profiles may be incompletely understood. These demands necessitate significant infrastructure, specialized expertise, and robust compliance mechanisms—resources that smaller or less well-established sites may find difficult to sustain. Furthermore, escalating regulatory requirements and administrative burdens pose additional obstacles to the activation and ongoing management of clinical trial sites, effectively raising the entry threshold for many institutions.

These competitive dynamics tend to create a reinforcing feedback loop wherein high-performing, resource-rich sites become the preferred partners for pharmaceutical sponsors seeking reliable and efficient trial execution. Such sites accrue greater experience, develop expansive research teams, and enhance their reputations, thereby further attracting subsequent trials. Conversely, lower-volume sites may struggle to maintain capacity and visibility, reducing their ability to compete effectively for new studies and exacerbating the decline in site diversity.

Interestingly, not all lower-volume sites suffered diminished trial activity. Sites integrated within the National Cancer Institute Community Oncology Research Program (NCORP) demonstrated relative resilience, maintaining much of their trial engagement throughout the period. This observation suggests that infrastructure support, resource sharing, and network integration provided by programs like NCORP may serve as critical buffers against the systemic pressures driving centralization. Such models underscore the potential value of collaborative frameworks in preserving and enhancing diversity within the clinical trial ecosystem.

Addressing the ongoing shift toward trial consolidation will necessitate coordinated multi-stakeholder strategies. Concerted efforts aimed at reducing barriers to site activation, enhancing infrastructure capabilities at smaller or community-based sites, and instituting policy incentives designed to encourage a more geographically balanced portfolio of trial sites are paramount. Without these interventions, the risk is that clinical trials will become increasingly detached from the broader patient populations they aim to serve, thereby undermining both scientific rigor and equitable access.

The present analysis carries certain limitations that warrant acknowledgment. The heterogeneity inherent in ClinicalTrials.gov data complicates precise identification of whether proximate sites represent discrete institutions or satellite branches of a larger entity, potentially influencing site counts. Additionally, lack of access to patient enrollment figures precludes direct assessment of actual participant distribution, meaning the number of active recruiting sites may be overestimated relative to trial instance counts. Moreover, the focus on phase I NSCLC trials may not fully extrapolate to other cancer subtypes or later-phase studies, which often entail different operational paradigms and risk profiles.

Future investigations are anticipated to expand these foundational insights by examining later-phase trials, which tend to have more established safety parameters and might allow broader site participation. Such comparative analyses could elucidate whether the trends of site consolidation observed in early-phase NSCLC trials are pervasive across oncology clinical research or largely confined to this niche. These forthcoming studies will be critical in shaping informed policies to promote inclusivity and scientific robustness in cancer drug development.

This body of work was supported by the LUNGevity Foundation through unrestricted grants, and the investigators have disclosed no conflicts of interest, underscoring their commitment to unbiased scientific inquiry. The findings presented here not only highlight the evolving challenges within the clinical trial landscape for lung cancer but also serve as a clarion call for renewed efforts to ensure that the future of oncology research remains accessible, diverse, and effective for all patients.

Subject of Research: Phase I clinical trials distribution and consolidation in non-small cell lung cancer (NSCLC) in the United States.

Article Title: Consolidation Trends in U.S. Phase I NSCLC Clinical Trial Sites Between 2020 and 2024.

News Publication Date: April 2026 (based on AACR Annual Meeting 2026 presentation date).

Web References:

• American Association for Cancer Research (AACR) Annual Meeting 2026: https://www.aacr.org/meeting/aacr-annual-meeting-2026/
• ClinicalTrials.gov database.

Keywords: non-small cell lung cancer, NSCLC, phase I clinical trials, trial site consolidation, clinical trial access, FDA Oncologic Drug Advisory Committee, trial decentralization, clinical research infrastructure, National Cancer Institute Community Oncology Research Program (NCORP), early-phase oncology trials, clinical trial representation, geographic diversity in trials.

Analyzing data from ClinicalTrials.gov records from 1995 through 2024, researchers have identified significant yet insufficient trends that reflect how clinical studies approach cancer cachexia. Notably, the inclusion of female participants has increased over time, indicating a broader recognition of sex differences in disease manifestation. However, despite this progress, the systematic reporting and analysis of sex as a biological variable remain surprisingly rare, limiting the deep understanding required to tailor interventions effectively.

An even more glaring deficit is revealed in the demographic breakdown of trial participants. Approximately 93% of individuals involved in these clinical trials are of Caucasian descent, exposing a glaring lack of diversity and representation from non-white populations. This lack of inclusivity raises concerns about the generalizability of study results across different ethnic groups, given that genetic and socio-environmental factors heavily influence cachexia’s development and progression.

Adding layers to this complexity is the striking heterogeneity observed in both the diagnosis and measurement of cancer cachexia across studies. Trials employ a vast array of diagnostic criteria and assessment tools, reflecting an absence of standardized protocols or universally accepted definitions. This variability impedes the ability to compare outcomes, synthesize data, or combine findings in meta-analyses, fracturing progress and slowing therapeutic innovation.

The review also underscores a pronounced neglect in considering critical clinical variables such as cancer type and stage. Cachexia does not affect all cancers uniformly; differing tumor biology and disease progression stages significantly influence the syndrome’s onset and severity. Yet, most studies fail to stratify or analyze patients along these lines, missing opportunities to uncover nuanced mechanistic insights or identify subgroup-specific treatment responses.

Such fragmented approaches ultimately contribute to the broader challenge of translating clinical trial results into effective, personalized care for cancer patients suffering from cachexia. While the body of research is undeniably growing, these underreported variables and methodological inconsistencies result in an incomplete picture that risks marginalizing those who do not fit the predominant study profiles, especially non-white individuals and females.

The implications within the broader biological and clinical research communities are profound. With mounting evidence emphasizing human heterogeneity—be it genetic, environmental, or physiological—the cancer cachexia field must evolve beyond a one-size-fits-all mindset. This calls for the urgent development and adoption of consensus definitions and standardized diagnostic and assessment tools that reflect the diverse realities of patient populations worldwide.

Emerging methodologies, including advanced biomarker panels, imaging techniques, and comprehensive phenotyping, offer promising avenues to refine the detection and mechanistic understanding of cachexia. Integrating these novel tools into clinical trial designs could revolutionize patient stratification and enable more accurate monitoring of disease progression and treatment efficacy, addressing long-standing obstacles.

Moreover, the ethical imperative to include diverse populations in clinical research transcends scientific rigor, touching on equity and fairness in healthcare access and outcomes. Enhancing representation ensures that the benefits derived from advances in cachexia management are equitably distributed and that all patient subgroups receive the most appropriate care based on robust evidence.

Parallel to incorporating patient diversity, the recognition of sex as a critical biological variable must become non-negotiable in future studies. Sex-based differences in hormonal milieus, metabolic pathways, and immune responses profoundly affect cachexia’s clinical manifestation. Detailed analyses in this regard could unveil sex-specific therapeutic targets or intervention strategies, improving overall treatment personalization.

By revisiting and updating the cachexia consensus framework regularly, researchers and clinicians can remain aligned with contemporary scientific insights and technological innovations. Such dynamic evolution is essential to keep pace with rapidly accumulating knowledge about cancer biology, systemic inflammation, metabolic dysregulation, and cachexia pathophysiology.

Critically, the current gaps highlighted by this landscape analysis act as a clarion call for multidisciplinary collaboration. Bridging oncologists, nutritionists, physiologists, immunologists, and data scientists will foster holistic approaches that capture the syndrome’s complexity and heterogeneity, facilitating the design of more rigorous and inclusive clinical trials.

Patient advocacy and engagement should also play a central role, as real-world experiences and priorities help guide meaningful endpoint selection and trial design, ensuring that outcomes resonate with patient needs beyond mere biometrics. Incorporating patient-reported outcomes can refine our understanding of cachexia’s impact on quality of life and treatment tolerability.

Ultimately, this retrospective examination of nearly three decades of clinical trials in cancer cachexia underscores both the progress achieved and the considerable work ahead. It reveals a landscape marked by incremental advances but also hampered by methodological disparities and demographic homogeneity, challenging the field to embrace inclusivity and standardization.

The hope is that this reflective review will stimulate the scientific community to heed these recommendations, fostering trials that are not only scientifically robust but also socially equitable. Through such endeavors, the pursuit of effective cachexia therapies can gain renewed momentum, translating into tangible improvements in patient outcomes worldwide.

As cancer continues to threaten millions globally, addressing cachexia with rigor and compassion becomes an ethical and clinical priority. This expansive reassessment stands at the forefront of efforts to reshape research paradigms, catalyze innovation, and ultimately alleviate the heavy burden cachexia imposes on patients and their families.

Subject of Research:
Cancer cachexia and trends in clinical trial design and participant demographics over the period 1995–2024.

Article Title:
Landscape of clinical trials in cancer cachexia: assessment of trends from 1995–2024.

Article References:
Cabrera, A.R., Parker, K., Snoke, D.B. et al. Landscape of clinical trials in cancer cachexia: assessment of trends from 1995–2024. BMC Cancer 25, 1265 (2025). https://doi.org/10.1186/s12885-025-14555-5

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14555-5

The article elucidates how persistent disparities in the inclusion of marginalized and underrepresented groups skew research outcomes, limit generalizability, and ultimately perpetuate health inequities. Historically, many biomedical studies have disproportionately focused on populations of European descent, male subjects, or economically advantaged individuals, neglecting key demographic and social variables. This narrow lens compromises the external validity of findings and constrains the development of universally effective interventions. Recognizing these flaws, the authors argue that investment in equitable research frameworks can catalyze breakthroughs in understanding and addressing complex pediatric health challenges.

At its core, equitable research entails the intentional design and execution of studies that incorporate diversity at every stage—from conception to dissemination. Suleman and colleagues provide a nuanced exploration of technical and ethical strategies that can be employed to operationalize equity. This includes diverse recruitment protocols that account for race, ethnicity, socioeconomic status, geographic location, gender identity, and disability status. Additionally, thoughtful data collection and analysis methodologies are vital to unravel the nuanced interplay between biological and social determinants of health.

One of the pivotal technical challenges highlighted is the development of robust demographic stratification methods. Traditional analyses often either adjust for confounders through simplistic covariate inclusion or neglect intersectionality altogether. To truly elevate the quality of research, there is an urgent need to implement advanced statistical modeling techniques that can capture complex interactions among variables such as systemic racism, environmental exposures, and genetic predispositions. This multidimensional approach allows researchers to uncover hidden patterns and address root causes of health disparities.

The article stresses that equitable research requires not only enhanced technical rigor but also a fundamental reorientation of funding priorities and institutional policies. Current funding mechanisms often reward incremental advances over transformative change, and many research infrastructures inadvertently propagate exclusion by failing to support community engagement or collaborative partnerships. The authors advocate for systemic investments that facilitate sustained engagement with historically marginalized communities, enabling co-creation of research agendas that are culturally relevant and responsive.

Another compelling dimension examined is the ethical imperative of equitable research. Beyond improving scientific validity, equity fosters trust between researchers and communities, an essential ingredient for participation and data integrity. Historically, breaches in ethical conduct—such as exploitative practices or lack of transparency—have led to justified skepticism and reticence among vulnerable populations. By prioritizing equity, researchers can build long-term partnerships grounded in respect, shared decision-making, and benefit sharing, thereby enhancing both recruitment and retention in research studies.

Suleman and colleagues also address the pedagogical aspects of equitable research, emphasizing the need for comprehensive training of investigators in cultural humility and structural competency. Such training enables researchers to recognize their own biases and the systemic factors that shape health disparities, thus promoting the design of studies that are both scientifically robust and socially conscientious. Importantly, this kind of education must be embedded throughout all levels of research training and professional development.

The article provides concrete examples of transformative research initiatives that have successfully integrated equity principles. For instance, community-based participatory research (CBPR) models exemplify how equitable partnerships can lead to richer data and more impactful interventions. These models dismantle traditional top-down approaches by empowering community stakeholders as active collaborators rather than passive subjects. The ripple effects include not only improved health outcomes but also strengthened social capital and capacity within underserved populations.

Importantly, the authors propose metrics and accountability frameworks to evaluate and incentivize equity in research. Standardized reporting of demographic diversity, equity-focused review processes, and public disclosure of equity outcomes are among the recommendations. Implementation of such metrics underscores accountability and transparency, helping to maintain momentum in the shift toward more inclusive science.

From a technological standpoint, innovations in data science and digital health offer promising tools to advance equitable research. The proliferation of mobile health technologies, telemedicine, and wearable devices can help bridge geographic and logistical barriers faced by marginalized groups. However, as the authors caution, attention must be paid to the digital divide to avoid exacerbating inequities. Strategies to enhance digital literacy and infrastructure are essential complements to these technological advances.

The article concludes with a visionary appeal: equitable research should be embedded not as a peripheral concern but as a foundational pillar of scientific inquiry. This requires concerted efforts by funders, academic institutions, policymakers, and researchers themselves to redesign systems and structures that have historically excluded large swathes of the population. By doing so, the entire research enterprise stands to gain in rigor, relevance, and ultimately, impact.

Furthermore, the ongoing COVID-19 pandemic has underscored the consequences of neglecting equity in research. Disparate outcomes observed globally and nationally have highlighted how failing to incorporate equity leads to blind spots that impair public health responses. The lessons from the pandemic serve as a clarion call to invest rigorously in designing and conducting research that reflects the full spectrum of human diversity.

Investing in equitable research also has important economic implications. Health disparities lead to increased healthcare costs, loss of productivity, and societal burdens. Therefore, by reducing inequities through better research, societies can anticipate downstream cost savings and improved quality of life. This macroeconomic argument strengthens the case for proactive allocation of resources toward equity-focused science.

Moreover, the authors touch upon the importance of translating equitable research into policy and practice. Research findings must inform health policy decisions and clinical guidelines in ways that promote equity rather than widen gaps. Effective knowledge translation requires ongoing dialogue among researchers, policymakers, and communities to ensure that innovations reach those most in need.

In essence, this groundbreaking perspective redefines the research enterprise as a socially embedded and justice-oriented endeavor. It challenges the status quo by asserting that methodological excellence and ethical rigor are intertwined with equity and inclusion. The implications of this paradigm shift are profound, promising a more enlightened, impactful, and humane scientific future.

In this context, the investment in doing equitable research right is not an optional add-on but an indispensable strategy for advancing pediatric health and beyond. Suleman, Keller, Ragavan, and their team have eloquently articulated how embracing equity enriches the scientific endeavor and propels us toward discoveries that truly serve all humanity. As this momentum grows, it sets a new standard for what it means to conduct research that is not only better but also just.

Subject of Research: Not explicitly detailed in the article excerpt, but pertains broadly to equitable research practices within pediatric health.

Article Title: Equitable research is better research: let’s invest in doing it right.

Article References:
Suleman, S., Keller, D., Ragavan, M.I. et al. Equitable research is better research: let’s invest in doing it right. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04119-5

Image Credits: AI Generated